Erik Manting - Jun 22, 2022 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Director
Signature
/s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Stock symbol
RNAZ
Transactions as of
Jun 22, 2022
Transactions value $
$0
Form type
4
Date filed
6/22/2022, 08:24 PM
Previous filing
Jul 8, 2021
Next filing
May 10, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.